On August 7, 2025, Two Seas Capital, the largest shareholder of Core Scientific, publicly announced its intention to vote against the proposed sale of Core Scientific to CoreWeave. This opposition was conveyed through an open letter.
The shareholder's stance introduces significant uncertainty regarding the completion of the $9 billion all-stock acquisition. The deal, announced on July 7, 2025, is contingent on shareholder approval.
This development could complicate CoreWeave's strategic plans to vertically integrate its infrastructure and eliminate future lease obligations. It highlights potential challenges in gaining full support for the acquisition from Core Scientific's investor base.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.